Langaee TY - Search Results

1

Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.

Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-Dehoff RM, Beitelshees AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Duarte JD, et al. Among authors: langaee ty. J Transl Med. 2012 Mar 22;10:56. doi: 10.1186/1479-5876-10-56. J Transl Med. 2012. PMID: 22440088 Free PMC article. Clinical Trial.

2

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.

Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Aquilante CL, et al. Among authors: langaee ty. Pharmacotherapy. 2004 Jun;24(6):720-6. doi: 10.1592/phco.24.8.720.36074. Pharmacotherapy. 2004. PMID: 15222661

3

CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78).

Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arant CB, Wessel TR, Schofield RS. Zineh I, et al. Among authors: langaee ty. Cytokine. 2006 Mar 7;33(5):258-63. doi: 10.1016/j.cyto.2006.02.008. Epub 2006 Mar 29. Cytokine. 2006. PMID: 16567110

4

Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene.

Zineh I, Welder GJ, Langaee TY. Zineh I, et al. Among authors: langaee ty. Clin Chim Acta. 2006 Aug;370(1-2):72-5. doi: 10.1016/j.cca.2006.01.025. Epub 2006 Mar 29. Clin Chim Acta. 2006. PMID: 16574090

5

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Aquilante CL, et al. Among authors: langaee ty. Clin Pharmacol Ther. 2006 Apr;79(4):291-302. doi: 10.1016/j.clpt.2005.11.011. Epub 2006 Feb 28. Clin Pharmacol Ther. 2006. PMID: 16580898 Clinical Trial.

6

Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.

Aquilante CL, Langaee TY, Anderson PL, Zineh I, Fletcher CV. Aquilante CL, et al. Among authors: langaee ty. Clin Chim Acta. 2006 Oct;372(1-2):195-8. doi: 10.1016/j.cca.2006.02.046. Epub 2006 May 15. Clin Chim Acta. 2006. PMID: 16701601

7

Common laboratory methods in pharmacogenomics studies.

Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Aquilante CL, et al. Among authors: langaee ty. Am J Health Syst Pharm. 2006 Nov 1;63(21):2101-10. doi: 10.2146/ajhp060068. Am J Health Syst Pharm. 2006. PMID: 17057047

8

Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.

Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, Johnson JA. Shin J, et al. Among authors: langaee ty. Am J Cardiol. 2007 Jan 15;99(2):250-5. doi: 10.1016/j.amjcard.2006.08.020. Epub 2006 Nov 21. Am J Cardiol. 2007. PMID: 17223428

9

Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.

Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Langaee TY, et al. Clin Pharmacol Ther. 2007 Mar;81(3):386-91. doi: 10.1038/sj.clpt.6100090. Clin Pharmacol Ther. 2007. PMID: 17339868 Clinical Trial.

10

Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit.

Gong Y, Beitelshees AL, Wessel J, Langaee TY, Schork NJ, Johnson JA. Gong Y, et al. Among authors: langaee ty. Pharmacogenet Genomics. 2007 Apr;17(4):267-75. doi: 10.1097/FPC.0b013e3280105235. Pharmacogenet Genomics. 2007. PMID: 17496725 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

155 results

Search Page